Citius Pharmaceuticals Inc. reported its earnings for the three months ended December 31, 2025. The company posted interest income of USD 0.05 million for the quarter. Interest expense totaled USD 0.16 million for the same period, primarily attributed to the March 28, 2025 letter agreement with Eisai and the note payable, including the fair value of the warrant issued to the lender. Stock-based compensation expense for the quarter increased by USD 1.76 million, mainly due to Citius Oncology restricted stock awards granted in September 2025. During the period, Citius Pharmaceuticals continued its focus on the development and commercialization of first-in-class critical care products. The company highlighted its obligations related to Citius Oncology, including milestone payments and tiered royalties to Dr. Reddy’s, as well as provisions for sublicensing revenue sharing. The company also noted the dissolution of Citius Pharmaceuticals, LLC in December 2023 and ongoing investments from previous equity offerings in money market accounts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-015878), on February 13, 2026, and is solely responsible for the information contained therein.